High-Density Lipoprotein Subclasses and Mild Cognitive Impairment: Study of Outcome and aPolipoproteins in Dementia (STOP-Dementia)1.
暂无分享,去创建一个
N. Murase | K. Kotani | N. Sakane | S. Nirengi | R. Ohtani | Michikazu Nakamura | M. Sainouchi | Y. Kuwata | M. Takata | Yuuichi Masuda
[1] T. Hatsukami,et al. HDL‐3 is a Superior Predictor of Carotid Artery Disease in a Case‐Control Cohort of 1725 Participants , 2014, Journal of the American Heart Association.
[2] Bruno Vellas,et al. Rationale for use of the Clinical Dementia Rating Sum of Boxes as a primary outcome measure for Alzheimer’s disease clinical trials , 2013, Alzheimer's & Dementia.
[3] P. Scheltens,et al. Regional atrophy is associated with impairment in distinct cognitive domains in Alzheimer's disease , 2014, Alzheimer's & Dementia.
[4] A. Alavi,et al. MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. , 1987, AJR. American journal of roentgenology.
[5] Thomas G. Cole,et al. Differences in the Aβ40/Aβ42 ratio associated with cerebrospinal fluid lipoproteins as a function of apolipoprotein E genotype , 2000 .
[6] J. Sicklick,et al. Neutrophil‐lymphocyte and platelet‐lymphocyte ratio as predictors of disease specific survival after resection of adrenocortical carcinoma , 2015, Journal of surgical oncology.
[7] M. Mackness,et al. Human paraoxonase-1 (PON1): Gene structure and expression, promiscuous activities and multiple physiological roles. , 2015, Gene.
[8] K. Kotani,et al. High-density lipoprotein size distribution can differ between subjects with alcoholic and non-alcoholic fatty liver disease. , 2014, Clinical laboratory.
[9] M. Taskinen,et al. Effect of HDL composition and particle size on the resistance of HDL to the oxidation , 2010, Lipids in Health and Disease.
[10] Caiyu Chen,et al. Cholesteryl Ester Transfer Protein Inhibitors in the Treatment of Dyslipidemia: A Systematic Review and Meta-Analysis , 2013, PloS one.
[11] Shaowu Cheng,et al. HDL and cognition in neurodegenerative disorders , 2014, Neurobiology of Disease.
[12] G. Vega,et al. LDL Phenotype in Subjects with Mild Cognitive Impairment and Alzheimer’s Disease , 2014, Journal of Alzheimer's disease : JAD.
[13] M C Hjortland,et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. , 1977, The American journal of medicine.
[14] S. Young,et al. Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation. , 1991, The Journal of clinical investigation.
[15] A. Gugliucci,et al. Paraoxonase 1 in neurological disorders , 2014, Redox report : communications in free radical research.
[16] Clinical assessment of cognitive functioning in the aged. , 1983, Psychopharmacology bulletin.
[17] H. Bloomfield,et al. Low-Density Lipoprotein and High-Density Lipoprotein Particle Subclasses Predict Coronary Events and Are Favorably Changed by Gemfibrozil Therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial , 2006, Circulation.
[18] J. Ruidavets,et al. High-density lipoprotein subclass profile and mortality in patients with coronary artery disease: Results from the GENES study. , 2016, Archives of cardiovascular diseases.
[19] C. Kalogeropoulou,et al. Advances in high-density lipoprotein physiology: surprises, overturns, and promises. , 2016, American journal of physiology. Endocrinology and metabolism.
[20] G. Norata,et al. High-Density Lipoprotein Subfractions - What the Clinicians Need to Know , 2013, Cardiology.
[21] M. Murray,et al. The presenilin 1 p.Gly206Ala mutation is a frequent cause of early-onset Alzheimer's disease in Hispanics in Florida. , 2016, American journal of neurodegenerative disease.
[22] Z. A. Oztürk,et al. The Evaluation of Neutrophil-Lymphocyte Ratio in Alzheimer’s Disease , 2012, Dementia and Geriatric Cognitive Disorders.
[23] T. Asada,et al. Amyloid-β sequester proteins as blood-based biomarkers of cognitive decline , 2015, Alzheimer's & dementia.
[24] M. Dobiášová,et al. Relations between particle size of HDL and LDL lipoproteins and cholesterol esterification rate. , 2005, Physiological research.
[25] C. Buhmann,et al. Characterization of four lipoprotein classes in human cerebrospinal fluid. , 2001, Journal of lipid research.
[26] T. Asada,et al. Efficacy and Blood Plasmalogen Changes by Oral Administration of Plasmalogen in Patients with Mild Alzheimer's Disease and Mild Cognitive Impairment: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial , 2017, EBioMedicine.
[27] I Litvan,et al. The FAB: A frontal assessment battery at bedside , 2000, Neurology.
[28] D. Catalucci,et al. Neutrophils promote Alzheimer's disease–like pathology and cognitive decline via LFA-1 integrin , 2015, Nature Medicine.
[29] L. Opie,et al. Association between ethnicity and obesity with high-density lipoprotein (HDL) function and subclass distribution , 2016, Lipids in Health and Disease.
[30] Xiao-lin Li,et al. HDL subfractions and very early CAD: novel findings from untreated patients in a Chinese cohort , 2016, Scientific Reports.
[31] M. Benson,et al. Nomenclature 2014: Amyloid fibril proteins and clinical classification of the amyloidosis , 2014, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
[32] C. Wellington,et al. High-density lipoproteins and cerebrovascular integrity in Alzheimer's disease. , 2014, Cell metabolism.
[33] S. Folstein,et al. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.
[34] Shunichiro Shinagawa,et al. Differentiation between amnestic‐mild cognitive impairment and early‐stage Alzheimer's disease using the Frontal Assessment Battery test , 2011, Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society.
[35] K. Kotani,et al. The relationship between adiponectin, an adiponectin gene polymorphism, and high-density lipoprotein particle size: from the Mima study. , 2012, Metabolism: clinical and experimental.
[36] C. Rowe,et al. An increased neutrophil–lymphocyte ratio in Alzheimer's disease is a function of age and is weakly correlated with neocortical amyloid accumulation , 2014, Journal of Neuroimmunology.
[37] J. Dietschy. Central nervous system: cholesterol turnover, brain development and neurodegeneration , 2009, Biological chemistry.
[38] M. Emul,et al. Neutrophil and platelet to lymphocyte ratios in people with subjective, mild cognitive impairment and early Alzheimer's disease , 2017, Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society.
[39] H. Matsuda,et al. An easy Z-score imaging system for discrimination between very early Alzheimer's disease and controls using brain perfusion SPECT in a multicentre study , 2007, Nuclear medicine communications.
[40] T. Kudo,et al. Association between CAG repeat length in the PPP2R2B gene and Alzheimer disease in the Japanese population , 2011, Neuroscience Letters.
[41] Yucheng Chen,et al. The Value and Distribution of High-Density Lipoprotein Subclass in Patients with Acute Coronary Syndrome , 2014, PloS one.